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There is limited data evaluating the feasibility of combining rit-
uximab with conditioning chemotherapy (or chemo-radiotherapy)
for patients undergoing allogeneic hematopoietic cell transplanta-
tion (allo-HCT). Twelve patients (M 5 7; F 5 5), with median
age of 54.5 (41–66) years, underwent allo-HCT for the following
diagnoses (disease-status at transplantation) [chronic lymphocytic
leukemia (CLL)5 7 (CR2 5 2; PR2 5 3; $PR3 5 2); mantle cell
lymphoma (MCL)5 3 (CR1 5 1; $PR2 5 2); follicular NHL 5 1
(CR3 5 1), diffuse large B-cell (DLBC) NHL 5 1 (.PR3 5 1)].
Donors were as follows: matched-related donors (MRD) 5 7;
matched-unrelated donors (MUD) 53; mismatched donor
(MMD)5 2. Fludarabine-based regimens comprised fludarabine
plus targeted doses of intravenous busulfan (FLU-BU 5 8), or to-
tal-body irradiation (FLU-TBI 5 3), or cyclophosphamide (FLU-
CY 5 1). Anti-thymocyte glogulin (ATG) was administered in
MMD cases. GVHD prophylaxis consisted of tacrolimus plus my-
cophenolate mofetil5 8, or methotrexate5 4. Nine (75%) patients
received rituximab 375 mg/m2 on days11 (63 days) and all (100%)
received rituximab 375 mg/m2 on day18 (63 days) without serious
infusion reactions. All patients engrafted. Median time to neutro-
phil engraftment for entire cohort was 15.5 (12–21) days. Median
time to platelet engraftment in 8 patients was 13.5 (10–18) days.
Four patients never dropped their platelet counts below 20,000/
uL. Median donor chimerism at day 190 (610 days) for unsorted
BM, CD3 and CD33 by PCR/STR were 95% (70–100%), 87.5%
(59–100%) and 100%, respectively. At a median follow-up of 6
(2.2–32) months, the 100-day non-relapse mortality in 11 evaluable
patients was 10%. Acute GVHD, grades II, III, IV, developed in
58%, 8.3% and 8.3%, respectively, at a median of 28 (16–77)
days. Response rates, at day1100 (610 days), according to diagno-
sis, in 10 evaluable patients were as follows: CLL (CR5 4/5; PR5
1/5); MCL: (CR5 3/3); follicular NHL (CR5 1/1); DLBC: (pro-
gressive disease 5 1/1). Administration of rituximab is feasible and
does not affect timely hematopoietic engraftment in allo-HCT re-
cipients with advanced CD201 malignancies.331
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Background: Peripheral blood hematopoietic stem cells (PBSC)
mobilized with granulocyte colony stimulating factor (G-CSF) are
increasingly used for hematopoietic rescue in transplant proce-
dures. G-CSF mobilization results in adequate PBSC collection
in most healthy donors after 1 or 2 apheresis procedures. However,
factors affecting mobilization have not been elucidated. A recent
study showed that smoking cessation was associated with a rapid in-
crease in circulating vascular endothelial progenitor cells (VEPC) in
peripheral blood. Hence, we evaluated the effect of smoking on
PBSC mobilization. Methods: All healthy donor PBSC collections
at our center were included. Data on donor age, sex, weight, G-CSF
dose and schedule, total CD341 cells collected and time to engraft-
ment, were reviewed. Data on smoking were categorized as current,
past and never smokers. Poor mobilization was defined as collection
of less than 2  106 CD341 cells/kg after a single apheresis proce-
dure processing 10 liters of blood.Results: 368 healthy donors were
included from 1993 to 2007. Of these, 192 (52%) never smoked, 92
(25%) were current smokers, 59 (16%) were past smokers and the
status of 25 (7%) was unknown. 122 (33%) healthy donors were
found to be poor mobilizers by our definition. Distribution of cur-
rent, past and never smokers was similar between good and poor
mobilizers (p 5 0.34). There was no significant difference between
poor mobilization and current, past or never smoking status.However, a small effect trending toward poorer mobilization
amongst current smokers (p 5 0.20) versus never/past smokers
and ever smokers (p 5 0.15) versus never smokers was identified.
Poor mobilization was related to delayed engraftment (p 5 0.03).
We failed to detect significant association between smoking history
and time to engraftment. Conclusions: Smoking seems to have
a small, if any, impact on mobilization of hematopoietic stem cells.
The lack of significant effect of smoking may be due to several rea-
sons:
- Effects of smoking may be more pronounced in the steady state.
- Stimulation by growth factors (G-CSF) may have blunted this ef-
fect.
- Effect of smoking on the stem cells and marrow stroma may be
more pronounced in diseased individuals (i.e. autologous donors).
This study was limited to healthy donors.
- Smoking may have a differential effect on VEPC versus hemato-
poietic stem cells.
Studies on PBSC mobilization in individuals undergoing autolo-
gous transplant may shed further light on this issue.332
ALEMTUZUMAB (ALEM) AND CONTINUOUS-INFUSION PENTOSTATIN
(PENTO): A NOVEL NONMYELOABLATIVE (NM) PREPARATIVE REGI-
MEN FOR ALLOGENEIC (ALLO) HEMATOPOIETIC CELL TRANSPLANTA-
TION (HCT)
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Current NM preparative regimens for allo HCT consistently
cause significant post-HCT neutropenia and thrombocytopenia.
To test the hypothesis that pre-HCT immunosuppression alone al-
lows engraftment without significant myelosuppression, we are
evaluating a preparative regimen of continuous-infusion PENTO
(12 mg/m2 over 72 hr, days -8 through -6) and ALEM (20 mg/
day, days -5 through -1) for allo HCT in high-risk patients (pts)
with hematologic malignancies. To date, 5 pts (median age, 64 yr;
range, 54–69 yr) with AML (3 pts), CLL (1 pt), or multiple myeloma
(MM) (1 pt) have been enrolled on this trial; 2 pts (1 AML, 1 MM)
had failed previous autologous HCT. The median interval between
most recent conventional chemotherapy (chemoRx) and allo HCT
was 3 (range, 2–5) mo. All pts received G-CSF mobilized PBSCs
from 8/8 HLA-matched unrelated donors; median cell doses were
2.86 (range, 1.86–6.0)  106 CD341 cells/kg and 3.33 (range,
1.57–4.46)  108 CD31 cells/kg. Cyclosporine (CSA) was used
for GVHD prophylaxis. All pts had asymptomatic transient eleva-
tions of AST and ALT (CTCAE grade 2–3) between days -6 and
-2. Median duration of hospitalization post-HCT was 6 (range,
3–62) days. The median nadir of absolute neutrophil count was
0.75 (range, 0.18–1.42)  109/L at a median of day 116 (range,
day 111-day 121), and the median nadir of platelet count was 46
(range, 18–183)  109/L at a median of day 16 (range, day 11-
day 119). In contrast, the nadir of absolute lymphocyte count
(ALC) was 0 in all pts at a median of day 12 (range, day 0-day
112); at day 128, the median ALC was only 0.096 (range, 0.055–
0.32)  109/L. One pt developed grade II acute GVHD at day
121. Two pts had asymptomatic CMV reactivation at days 15
and111, respectively. At day128, bone marrow chimerism studies
showed a median of 27% (range, 13–100%) donor DNA. At day
1100, 3 of 4 evaluable pts had 38%, 84% and 100% donor chime-
rism, respectively; the pt with 38% donor DNA had recurrent MM,
and upon cessation of CSA, donor chimerism increased to 64% by
day 1124. One pt had no donor engraftment at day 1100 and had
the longest interval (5 mo) between conventional chemoRx and allo
HCT. Four pts are alive at a median of 1591 days (range, 461-2561)
after HCT; one pt with AML relapsed and died of GVHD after
a second allo HCT. These encouraging results suggest that immu-
nosuppression with PENTO and ALEM is a novel NM HCT strat-
egy that allows donor cell engraftment without significant
myelosuppression.
